The Rare Oncology track will feature agencies, developers, and patient organizations who are in the trenches advancing rare cancer awareness, diagnosis, and treatment.
Keynote Panel: Advancing cell and gene therapy – considerations in manufacturing, R&D expertise, early payer engagement and continuous patient centricity
Moderator: Sophie Schmitz,Managing Partner, Partners4Access
2:30 ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30min) – SPONSORED ROUNDTABLES AVAILABLE
ROUNDTABLE 10: Data ownership – addressing the need for increased data sharing while also considering company/patient data "ownership" through clinical trials and beyond
ROUNDTABLE 12: Chilling investment? – the potential implications of increased public scrutiny of rare disease drug prices in the US
ROUNDTABLE 13: Cross-Ecosystem collaborations – mutual value propositions and collaborations for pharma, payers and providers to collaborate in the rare diseases space
ROUNDTABLE 5: Patient-focused research – new approaches to bring clinical trials directly to patients and change the patient-centric trial paradigm in rare diseases
ROUNDTABLE 6: Patient-centered Development: Early patient input, understanding patient goals in clinical trials, and furthering relationships between all stakeholders
ROUNDTABLE 7: Meaningful endpoints – navigating the differences in what it means to patients, caregivers, physicians and regulators during advanced therapies clinical development
ROUNDTABLE 20: Combining imaging and genomics analysis – integration of multi-modal data analysis to accelerate and de-risk drug development in rare diseases